Fairvalue-Calculator Fairvalue-Calculator
EN DE

Cuprina Holdings (CUPR) Fair Value & Analysis

Healthcare · US · Market cap $11.7M

Price$3.94
Fair Value$5.89
Upside+49.5%
Quality95/100
Evidence: Low Range $4.42 – $7.37

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Cuprina Holdings (CUPR) currently trades at $3.94, while our model-based Fair Value estimate is $5.89 — implying the stock looks roughly 49.5% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Cuprina Holdings (Cayman) Limited, a biomedical and biotechnology company, focuses on the development and commercialization of products for the management of chronic wounds. The company manufactures and distributes a line of medical grade sterile blowfly larvae bio-dressing products used as a biological debridement tool for chronic wounds under the MEDIFLY brand name. It is also developing collagen dressings, including sponges, particles, and hydrogels using bullfrog collagen derived from the valorization of abattoir waste streams; and products using medical leeches for wound treatment. The company was founded in 2019 and is based in Singapore. Cuprina Holdings (Cayman) Limited operates as a subsidiary of Cuprina Holding Pte. Ltd.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Cuprina Holdings (CUPR) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $5.89 versus a price of $3.94 — about +49% (undervalued). Model-based estimate, not financial advice.
What is the fair value of CUPR?
Our 21-model fair value for Cuprina Holdings is $5.89 (as of Jun 24, 2026), built from audited fundamentals. The current price is $3.94.
What is the quality score of CUPR?
Cuprina Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.